Financial Data and Key Metrics Changes - Agilent reported Q1 2026 revenue of $1.8 billion, growing 4.4% on a core basis, with a reported growth of 7% [5][24] - Operating margins were 24.6%, in line with expectations, and down 50 basis points year-over-year due to increased tariff expenses [7][26] - Q1 EPS was $1.36, reflecting a 4% growth, and adjusted for the weather impact, it would have exceeded the midpoint of guidance [7][26] Business Segment Data and Key Metrics Changes - Agilent CrossLab Group (ACG) grew 6%, driven by strong consumables growth and solid performance in services [24] - Applied Markets Group (AMG) grew 4%, led by double-digit performance in spectroscopy [24] - Life Sciences and Diagnostics Group (LDG) grew 3%, slightly below expectations due to weather impact and softness in academia and government [25][60] Market Data and Key Metrics Changes - Pharma growth was 7%, with double-digit growth in biotech, supported by increased funding and M&A activity [17] - Advanced materials market grew 20%, driven by semiconductor reshoring and strong demand for atomic spectroscopy tools [18][80] - Environmental and forensics market was flat, while the food business declined 4%, outperforming expectations [18][19] Company Strategy and Development Direction - Agilent is focused on enhancing customer intimacy through differentiated service offerings and leveraging the Ignite operating system for operational excellence [8][15] - The company aims to capture opportunities from improving end markets, innovative products, and a multi-pronged replacement cycle [22] - Agilent is maintaining its expected core growth range of 4%-6% for the full year, with a focus on disciplined capital deployment and strategic M&A [22][31] Management's Comments on Operating Environment and Future Outlook - Management noted a solid start to the year with underlying momentum in key markets, despite challenges from weather and macroeconomic conditions [5][16] - The company expects continued growth in pharma, diagnostics, and advanced materials, with a billion-dollar addressable market opportunity from reshoring [21][22] - Management remains optimistic about the second quarter, expecting core growth of approximately 4%-5.5% [22][32] Other Important Information - Operating cash flow for Q1 was $268 million, with $93 million invested in CapEx and $152 million in share repurchases [27] - The company ended the quarter with a net leverage ratio of 0.8 turns, maintaining a strong balance sheet [27] - Agilent's Ignite operating system has delivered clear financial results, including pricing realization and procurement savings [15][30] Q&A Session Summary Question: Impact of the snowstorm and expectations for catch-up - Management confirmed a $10 million revenue impact from the snowstorm, with most of it already recovered, and a modest impact on margins [37][38] Question: Margin improvement cadence - The second quarter is expected to show a 50 basis point improvement driven by pricing, volume, and Ignite savings, offset by performance-based pay and tariffs [39][40] Question: Visibility on back half growth - Management highlighted strong underlying momentum in key markets, particularly in pharma and advanced materials, as drivers for growth in the second half [42][44] Question: Tariff assumptions post-Supreme Court ruling - Management stated that current guidance remains unchanged despite the dynamic tariff situation, with no significant changes expected [48][49] Question: Capital equipment demand trends - Management noted steady demand in capital equipment, with no signs of deterioration, and a reasonable budget flush observed at the end of December [52][54] Question: M&A environment and appetite - Management emphasized a disciplined approach to M&A, focusing on strategic fits and financial attractiveness, without needing transformative deals [55][56] Question: LDG segment performance - Management acknowledged challenges in the LDG segment due to weather and academic market softness, but expressed optimism for future improvements [60][62] Question: Specialty CDMO growth visibility - Management confirmed low double-digit growth in the specialty CDMO segment, with expectations for mid-teens growth for the full year based on production schedules [65][66]

Core Viewpoint - Waters Corporation's stock is trading lower following the release of its fourth-quarter 2025 financial results and fiscal 2026 guidance [1] Fourth Quarter Earnings Snapshot - The company reported quarterly sales of $932.36 million, a 7% increase as reported and 6% in constant currency, surpassing the consensus estimate of $928.09 million [2] - Sales in the academic and government market decreased by 2% as reported and 3% in constant currency [2] - Adjusted earnings were $4.53 per share, exceeding the consensus of $4.51 [2] Sales Performance - Instrument system sales increased by 3% as reported and in constant currency [3] - Recurring revenues, which include service and precision chemistries, rose by 10% as reported and 9% in constant currency [3] - Geographically, sales in Asia increased by 4% as reported and 11% in constant currency, while sales in the Americas rose by 4% as reported and in constant currency, and sales in Europe increased by 13% as reported and 4% in constant currency [3] Fiscal 2026 Guidance - The company anticipates continued momentum into 2026, driven by a multi-year instrument replacement cycle and innovation [4] - Initial guidance for 2026 indicates a combined company sales growth of 5.3% at the midpoint, with potential for outperformance [5] - Expected adjusted earnings for Q1 2026 are projected at $2.25-$2.35 per share, compared to the consensus of $2.52, with sales between $1.198-$1.211 billion [5] - For fiscal 2026, adjusted earnings are expected to be $14.30-$14.50 per share versus the consensus of $14.29, with sales projected at $6.41 billion-$6.46 billion [6] Analyst View - Analysts note that Waters' leadership in the QA/QC market benefits from multiple sector-level and idiosyncratic tailwinds, indicating the company is in the early to middle stages of a long-overdue replacement cycle [7] - The acquisition of BD Bio/Dx is expected to significantly expand the company's total addressable market (TAM) with conservative cost synergies and achievable revenue synergies [7] - Analysts expect "New Waters" to maintain above-group growth, margins, and return on invested capital (ROIC), suggesting the company will sustain a premium multiple [8]

Financial Data and Key Metrics Changes - The company achieved high single-digit reported revenue growth and low double-digit adjusted EPS growth in Q4 2025, with sales growing 7% on a reported basis and 6% in constant currency [5][7] - Adjusted EPS grew 11% to $13.13 for the full year, while GAAP EPS was $10.76 [9][33] - Recurring revenue grew 9%, driven by a 12% increase in chemistry [7][32] Business Line Data and Key Metrics Changes - Instrument revenue grew 5%, led by high single-digit growth in LCMS, while TA instruments declined due to cautious spending in the U.S. and Europe [9][30] - Chemistry revenue grew 12% for the full year, significantly above the historical average growth rate of 7% [12][33] - The transition to a subscription-based model for Empower reduced overall instrument growth by a low single-digit percentage for the quarter, but is expected to provide long-term recurring revenue benefits [8][48] Market Data and Key Metrics Changes - Pharma revenue grew 9%, with high single-digit growth across the Americas and Europe, and low double-digit growth in Asia [13][30] - In China, sales grew 9% for the year, driven by strong performance in biotech and CDMOs [14][33] - Non-pharma end markets saw industrial growth of 6%, while academic and government declined by 1% [13][32] Company Strategy and Development Direction - The company completed the acquisition of BD's Biosciences and Diagnostic Solutions business, aiming to strengthen its position in high-growth adjacencies and enhance operational execution [5][18] - The strategic roadmap laid out five years ago continues to advance, with a focus on innovation and commercial execution [6][9] - The company plans to expand its idiosyncratic growth driver framework from three to five drivers, adding biologics and informatics to its growth strategy [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving organic revenue growth of 5.5%-7% for 2026, with the acquired business expected to contribute $3 billion in revenue [26][35] - The company anticipates a blended year-over-year revenue growth of approximately 5.3% for the combined entity in 2026, with an adjusted operating margin percentage of approximately 28.1% [27][36] - Management highlighted the importance of improving operational execution and pricing discipline to enhance revenue synergies [44][52] Other Important Information - Free cash flow totaled $677 million for the full year, with a net debt position of $820 million at year-end [34][36] - The company expects to realize approximately $55 million of adjusted EBIT from cost synergies in 2026, alongside $50 million in revenue synergies [24][36] Q&A Session Questions and Answers Question: Insights on BD results and path to recovery - Management acknowledged several issues that impacted growth in the BD business, including a weaker flu season and challenges in export approvals, but expressed confidence in a lower baseline for 2026 to support recovery [42][46] Question: Impact of Empower transition on instruments - Management noted that the transition to subscription for Empower had a low single-digit headwind on overall instrument growth but is expected to provide long-term recurring revenue benefits [43][48] Question: Full year guidance and deceleration dynamics - Management clarified that the guidance reflects a prudent approach, incorporating assumptions of mid-single-digit growth in China and the impact of the Empower transition [49][50]

Core Insights - The replacement cycle for instruments has been ongoing for about a year, with significant momentum observed in orders outpacing revenues [1][2] - The growth rate for LC-MS instruments remains in the high single-digit range, driven by the replacement cycle and other factors [2][3] - The industry is still in the early stages of the replacement cycle, with many customer segments yet to begin replacing their instruments [3] Group 1 - The instrument replacement cycle is expected to continue, indicating a positive trend for future growth [3] - Current growth for LC-MS instruments is characterized by a low single-digit CAGR over the past six years, suggesting room for improvement [3] - The sales funnel for instruments is strong, indicating good future demand [3]